VGI Trugene Interpretation Software Showcased At Seville HIV/AIDS Meeting
This article was originally published in The Gray Sheet
Executive Summary
FDA's clearance process for future versions of Visible Genetics, Inc.'s HIV drug resistance assay interpretation systems may provide a key to how the agency will review next-generation genetic tests
You may also be interested in...
ViroLogic Vying For HIV Resistance Market Advantage As Rival Mulls Merger
ViroLogic's new HIV replication assay will help drive conversion of the resistance testing market from genotype to phenotype-based tests, the firm believes
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.